Source: Annual Congress 2009 - Fitness for radical therapy in lung cancer patients



Rating:

Share or cite this content

Citations should be made in the following way:
J-P. Sculier (Brussels, Belgium). Functional selection criteria before definitive radiotherapy and chemotherapy. Annual Congress 2009 - Fitness for radical therapy in lung cancer patients

Member's Comments

No comment yet.

Related content which might interest you: Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004 Contribution of FDG-PET on staging and management of NSCLC planned for concomitant chemoradiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 664s Year: 2007 Induction chemotherapy, concurrent chemoradiation and surgery for Pancoast tumour Source: Eur Respir J 2007; 29: 117-126 Year: 2007 Pitfalls of neoadjuvant treatment Source: Annual Congress 2012 - Current challenges in multimodality lung cancer treatment Year: 2012 Indcution chemotherapy and radiotherapy vs. induction and simultaneous radiochemotherapy in inoperable stage III NSCLC. Update on BROCAT study CTRT 99/97 Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006 Modern radiotherapy as a curative treatment modality for stage III NSCLC Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease Year: 2019 ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Source: Eur Respir J 2009; 34: 17-41 Year: 2009 Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Combined endoscopic evaluation of the effectiveness of neoadjuvant chemotherapy of NSCLC using autofluorescence and spectroscopic methods Source: Annual Congress 2011 - The basic and the future: pure diagnostic or dedicated wavelengths play Year: 2011 ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy) Source: Guideline 2009 Year: 2009 Is there any survival benefit of surgery after neoadjuvant chemoradiotherapy and persisting pn2/3 in stage III NSCLC? Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer Year: 2009 Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Induction chemotherapy and simultaneous radiochemotherapy or radiotherapy in inoperable NSCLC (stage IIIA/IIIB) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002 Adjuvant chemotherapy uptake and survival of patients with NSCLC after complete resection:  Single institution/single area experience. Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons Year: 2017 A higher-risk patient with a choice between stereotactic radiotherapy and surgery Source: International Congress 2019 – Lung cancer Grand Round Year: 2019 What outcome after the prescription of neoadjuvant chemotherapy in lung cancer? Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011